Left behind? Drug discovery in extensive-stage small-cell lung cancer

Jonathan Riess; Primo N Lara

doi:10.1016/j.cllc.2013.12.010

Left behind? Drug discovery in extensive-stage small-cell lung cancer

Jonathan Riess, Primo N Lara

Hematology and Oncology

Research output: Contribution to journal › Article › peer-review

11 Scopus citations

Abstract

Systemic therapy and subsequent survival for patients with extensive-stage small-cell lung cancer (SCLC) are poor and have remained unchanged in the past quarter century. To improve outcomes in these patients, a new drug development paradigm must be adopted that moves away from empiricism and instead focuses on tumor biology and heterogeneity as a means to increase target and drug class diversity. By incorporating tools that have led to new diagnostic and treatment options in non-small-cell lung cancer, there could be hope yet for the future of SCLC therapeutics.

Original language	English (US)
Pages (from-to)	93-95
Number of pages	3
Journal	Clinical Lung Cancer
Volume	15
Issue number	2
DOIs	https://doi.org/10.1016/j.cllc.2013.12.010
State	Published - Mar 2014

Keywords

Amrubicin
Chemotherapy
Clinical trials
Developmental therapeutics
Small cell lung cancer

ASJC Scopus subject areas

Cancer Research
Oncology
Pulmonary and Respiratory Medicine

Access to Document

10.1016/j.cllc.2013.12.010

Fingerprint Dive into the research topics of 'Left behind? Drug discovery in extensive-stage small-cell lung cancer'. Together they form a unique fingerprint.

Cite this

@article{08bec91e5df349bca134208f85306e9e,

title = "Left behind? Drug discovery in extensive-stage small-cell lung cancer",

abstract = "Systemic therapy and subsequent survival for patients with extensive-stage small-cell lung cancer (SCLC) are poor and have remained unchanged in the past quarter century. To improve outcomes in these patients, a new drug development paradigm must be adopted that moves away from empiricism and instead focuses on tumor biology and heterogeneity as a means to increase target and drug class diversity. By incorporating tools that have led to new diagnostic and treatment options in non-small-cell lung cancer, there could be hope yet for the future of SCLC therapeutics.",

keywords = "Amrubicin, Chemotherapy, Clinical trials, Developmental therapeutics, Small cell lung cancer",

author = "Jonathan Riess and Lara, {Primo N}",

year = "2014",

month = mar,

doi = "10.1016/j.cllc.2013.12.010",

language = "English (US)",

volume = "15",

pages = "93--95",

journal = "Clinical Lung Cancer",

issn = "1525-7304",

publisher = "Elsevier",

number = "2",

}

TY - JOUR

T1 - Left behind? Drug discovery in extensive-stage small-cell lung cancer

AU - Riess, Jonathan

AU - Lara, Primo N

PY - 2014/3

Y1 - 2014/3

N2 - Systemic therapy and subsequent survival for patients with extensive-stage small-cell lung cancer (SCLC) are poor and have remained unchanged in the past quarter century. To improve outcomes in these patients, a new drug development paradigm must be adopted that moves away from empiricism and instead focuses on tumor biology and heterogeneity as a means to increase target and drug class diversity. By incorporating tools that have led to new diagnostic and treatment options in non-small-cell lung cancer, there could be hope yet for the future of SCLC therapeutics.

AB - Systemic therapy and subsequent survival for patients with extensive-stage small-cell lung cancer (SCLC) are poor and have remained unchanged in the past quarter century. To improve outcomes in these patients, a new drug development paradigm must be adopted that moves away from empiricism and instead focuses on tumor biology and heterogeneity as a means to increase target and drug class diversity. By incorporating tools that have led to new diagnostic and treatment options in non-small-cell lung cancer, there could be hope yet for the future of SCLC therapeutics.

KW - Amrubicin

KW - Chemotherapy

KW - Clinical trials

KW - Developmental therapeutics

KW - Small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=84894180448&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894180448&partnerID=8YFLogxK

U2 - 10.1016/j.cllc.2013.12.010

DO - 10.1016/j.cllc.2013.12.010

M3 - Article

C2 - 24529447

AN - SCOPUS:84894180448

VL - 15

SP - 93

EP - 95

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

IS - 2

ER -

Left behind? Drug discovery in extensive-stage small-cell lung cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this